SCHEMBL6136274

SCHEMBL6136274

CCN(CCc1cccc(Cc2c(-c3ccc(O)cc3)ccc3cc(O)ccc23)c1)C(=O)Nc1ccc(OC)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 6/20 0.41
▸ MAPT P10636 2/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ ESR1 P03372 2/20 0.39
▸ ESR2 Q92731 2/20 0.39
▸ CYP3A4 P08684 2/20 0.38
▸ CYP2D6 P10635 2/20 0.38
▸ CYP2C9 P11712 2/20 0.38
▸ ROCK1 Q13464 2/20 0.38
▸ CDC42BPA Q5VT25 2/20 0.38
▸ TRPV1 Q8NER1 1/20 0.38
▸ BMP1 P13497 1/20 0.37
▸ MAPK1 P28482 1/20 0.36
▸ TOP2A P11388 1/20 0.36
▸ TOP2B Q02880 1/20 0.36
▸ MTNR1A P48039 1/20 0.36
▸ MTNR1B P49286 1/20 0.36
▸ PLG P00747 2/20 0.36
▸ KLK1 P06870 2/20 0.36
▸ KLK6 Q92876 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6135968 0.94 TRPV1 (0.41) ROCK2MAPTNPSR1ESR1ESR2
SCHEMBL6135989 0.90 GAA (0.40) ROCK2MAPTNPSR1ESR1ESR2
SCHEMBL6136417 0.90 NPY5R (0.45) ROCK2MAPTNPSR1ESR1ESR2
SCHEMBL6136103 0.86 ESR1 (0.45) ROCK2MAPTESR1ESR2CYP3A4
SCHEMBL6136383 0.84 NPY5R (0.43) ROCK2ESR1ESR2CYP3A4CYP2D6
SCHEMBL6136033 0.84 CNR1 (0.49) ROCK2MAPTESR1ESR2ROCK1
SCHEMBL6136266 0.81 MTOR (0.44) ROCK2ESR1ESR2ROCK1TRPV1
SCHEMBL6136057 0.80 NPY5R (0.40) ROCK2ESR1ESR2ROCK1TRPV1
SCHEMBL6136065 0.79 TRPV1 (0.47) ROCK2ESR1ESR2TRPV1
SCHEMBL6136139 0.79 MTOR (0.47) ROCK2MAPTESR1ESR2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0895989-B1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity LILLY CO ELI (US) 2005-05-18 — — EP claimed
US-6509356-B1 Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound ELI LILLY AND COMPANY 2003-01-21 — — US claimed
EP-0895989-A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity ELI LILLY AND COMPANY (US) 1999-02-10 — — EP claimed
EP-0895989-B1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity LILLY CO ELI (US) 2005-05-18 — — EP disclosed
US-6509356-B1 Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound ELI LILLY AND COMPANY 2003-01-21 — — US disclosed
EP-0895989-A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity ELI LILLY AND COMPANY (US) 1999-02-10 — — EP disclosed
Send feedback